Valuation
- Market cap
- 2,275,000
- Revenue TTM
- $0
- Net income TTM
- $-14,590,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 64,154,902
- Avg volume
- 2,111,514
- Day's range
- $0.88 – $1.59
- Shares out
- 2,013,000
- Stochastic %K
- 50%
- Beta
- 0.59
- Analysts
- Strong Buy
- Price target
- $47.99
Company profile
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia....
Show more
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 972 3 7177050
- Website
- https://www.painreform.com
- Address
- 65 Yigal Alon St., Tel Aviv, Israel
Latest news
No headlines yet.
